XML 116 R21.htm IDEA: XBRL DOCUMENT

Subsequent Event	12 Months Ended
Subsequent Event	Dec. 31, 2019
Subsequent Events [Abstract]
Subsequent Event	Subsequent Event On January 14, 2020, the FDA held an Advisory Committee meeting regarding our NDA for NKTR-181. The Advisory Committee voted against approval. We subsequently decided to withdraw our NDA and to make no further investments in this program. On February 26, 2020, the Audit Committee of our Board of Directors approved management’s plan for the wind-down of Inheris and the NKTR-181 program. As a result, in the first quarter of 2020, we expect to incur charges of $45.0 million to $50.0 million, including non-cash charges of $19.7 million for the impairment of advance payments to contract manufacturers for commercial batches of NKTR-181, as well as other charges, primarily for non-cancellable commitments to our contract manufacturers and certain severance costs.